Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein-centric drug development and functional glycomics enrich biopharmaceuticals pipeline

29.04.2004


Technical Insights biotechnology industry impact service



Researchers are beginning to see the potential for breakthrough in healthcare through glycomics, which studies carbohydrates, proteins and their interactions. In fact, these carbohydrates are moving beyond their regular roles as sugar storage bins. Carbohydrate-binding proteins are becoming extremely useful in curing various illnesses.

"The rapid evolution of glycomics as a natural extension of proteomics provides a better understanding of glycoproteins, glycosylation process, and its role in the protein function," explains Frost & Sullivan Industry Analyst Giridhar Rao. "This in turn facilitates the development of novel biodrugs."


The rapid progress of glycomics in the biopharmaceutical industry is evident from the existence of approximately half a dozen drugs, in which manipulation of carbohydrates and proteins provides advanced drug properties. For example, Epogen – a glycotherapeutic drug – contains two additional carbohydrate groups that can extend circulatory half-life and magnify efficiencies.

Active research on glycosyltransferases to understand the role of carbohydrate interactions in a cancerous cell is also likely to provide further opportunities for application of glycomics. One such prospect lies in the development of protein serum-based cancer diagnostics.

In fact, glycoprotein therapeutics is the fastest growing segment in the biopharmaceuticals industry with an annual growth rate of 24 percent, which is expected to accelerate further. However, maintaining adequate manufacturing capacity is a critical challenge.

"With around 100 protein-based drugs that are in late-stages of human clinical trials, few are likely to hit the market in the coming years," says Rao. "Hence, raising the demand for production capacity at least by four times more than the existing capacity. This may be essential to maintain the demand-supply equilibrium."

This creates an urgent need for alternate manufacturing media such as transgenic plants and animals, besides the mammalian and microbial and fungal cell culture systems.

Fungal cell lines provide considerable time and cost benefits over mammalian cell lines. For instance, the latter proves to be a lengthy process and may alter the properties of the final therapeutic glycoprotein.

Conversely, fungal cell lines such as engineered yeast expression systems for production of humanly glycosylated protein provide for faster fermentation and a higher product yield.

Industrial bioprocessing also holds immense potential for biotechnology. The development of a sophisticated microbioreactor for bacterial cell culture could speed up the bioprocessing mechanism.

A 5- to 50-microliter microbioreactor provides significant advantages over traditional chemical processes, such as lower temperature, pressure, and almost neutral pH requirements. Also, mass production with lesser power consumption is viable since the raw materials are renewable living cells.

Nano-biotechnology proves to be another potential growth area, where the endless possibilities of ’doing big with small’ exist. This has sparked an explosion of research and has influenced the commercialization of many nano drug delivery technologies.

For instance, the uniquely small-sized carbon buckyballs and nanotubes are proving to be successful nano-carriers that are small enough to navigate within the body. Thereby, they could serve as effective carriers of active ingredients for cancer treatment. However, dealing with the toxicity of trace nanoparticles that could be left behind in the body, is a major concern.

Another promising technique is nano-sized dendrimers that escape the blood stream through vascular pores, and selectively target and treat tumor cells. Dendrimer-based drugs coupled with additional agents provide high-end tumor images and hence could revolutionize cancer treatment.

Julia Paulson | EurekAlert!
Further information:
http://www.frost.com
http://www.technicalinsights.frost.com

More articles from Life Sciences:

nachricht Research team of the HAW Hamburg reanimated ancestral microbe from the depth of the earth
01.03.2017 | Hochschule für Angewandte Wissenschaften Hamburg

nachricht Researchers Imitate Molecular Crowding in Cells
01.03.2017 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

A better way to measure the stiffness of cancer cells

01.03.2017 | Health and Medicine

Exploring the mysteries of supercooled water

01.03.2017 | Physics and Astronomy

Research team of the HAW Hamburg reanimated ancestral microbe from the depth of the earth

01.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>